Faithward Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$916K Buy
996
+95
+11% +$96.3K 0.13% 135
2025
Q4
$968K Buy
901
+613
+213% +$586K 0.14% 130
2025
Q3
$220K Sell
288
-75
-21% -$55.8K 0.03% 287
2025
Q2
$283K Buy
+363
New +$282K 0.04% 224
2024
Q4
Sell
-643
Closed -$570K 280
2024
Q3
$570K Buy
643
+31
+5% +$27.9K 0.1% 153
2024
Q2
$554K Sell
612
-13
-2% -$10.4K 0.1% 152
2024
Q1
$486K Buy
+625
New +$445K 0.09% 158

Other funds holding LLY

Faithward Advisors's LLY Position: Q1 2026 in Review

Faithward Advisors increased its Eli Lilly (LLY) stake by 11% in Q1 2026, buying an estimated $96.3K and bringing the position to 996 shares worth $916K. The position accounts for 0.13% of the portfolio, ranked #135.

Faithward Advisors first reported a position in LLY in Q1 2024 and has held it in 7 quarters since. The position peaked at $968K in Q4 2025. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Faithward Advisors held 996 shares of Eli Lilly worth $916K as of Q1 2026.
  • Faithward Advisors bought 95 Eli Lilly shares in Q1 2026, an estimated $96.3K.
  • Eli Lilly made up 0.13% of Faithward Advisors's portfolio in Q1 2026, its #135 holding.
  • Faithward Advisors first reported a position in Eli Lilly in Q1 2024 and has held it in 7 quarters since.
  • Faithward Advisors's Eli Lilly position peaked at $968K in Q4 2025.
  • 4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Faithward Advisors's 13F filing for Q1 2026, filed 17 Apr 2026.